Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.

Dupont, Jeanette

Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. [electronic resource] - Acta oncologica (Stockholm, Sweden) 2007 - 330-5 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article

0284-186X

10.1080/02841860600949578 doi


Adenocarcinoma--drug therapy
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Capecitabine
Denmark
Deoxycytidine--administration & dosage
Disease Progression
Dose-Response Relationship, Drug
Drug Administration Schedule
Epirubicin--administration & dosage
Esophagogastric Junction--pathology
Female
Fluorouracil--administration & dosage
Follow-Up Studies
Humans
Male
Middle Aged
Organoplatinum Compounds--administration & dosage
Oxaliplatin
Severity of Illness Index
Stomach Neoplasms--drug therapy
Survival Analysis
Time Factors
Treatment Outcome